top of page

BPIQ Q2 2023 Biotech Hedge Fund (13F) Analysis

Updated: Aug 22, 2023

Last updated 8/15/23


  • Hedge fund holdings can help you discover new investment ideas

  • Get more stock idea and see the full list of most popular stocks amongst biotech hedge funds with Premium. Learn more here!

  • Want added conviction on your current investments? See how many of the funds hold your favorite companies? Find out in our Hedge Fund Screener tool here

  • Also see our new deeper insight BPIQ article for new tables of quarterly moves and upcoming readouts!

Already an Elite member? See the deeper article here.

About Our Hedge Fund Analysis

At BPIQ we track quarterly 13F filings for some of the largest, best known biotech hedge funds. Several Q4 2022 13F filings have already been made available, and all must be made available by tomorrow, February 14, 2023. This quarter we will analyze 36 funds, which we believe are all life science hedge funds. Some of these funds include:

  • EcoR1

  • RA Capital

  • Baker Brothers

  • Perceptive Advisors

  • Orbimed Partners

  • Opaleye

  • NEA Management

  • Logos

  • Casdin

  • Vivo

  • Cormorant

  • Redmile Group.

Like most biotech investors, most of these funds had a tough year in 2021 (See "Hedge Funds Suffer Big Losses in Biotech Rout" (The Wall Street Journal 12/6/21)) and likely have had troubles in the 1st half of 2022, as headwinds from the biotech sector pushed hard against even the most experienced biotech investors. However, biotech's resurgence since mid-June 2022 has probably led to a resurgence into the biotech funds as well.


Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter


Want added conviction on your current investments? See how many of the funds hold your favorite companies? Find out in our Hedge Fund Screener tool here

Figure 1. BPIQ Hedge Fund search tool

Top 20 Holdings (sneak preview)

We analyzed the Top 20 holdings in all top biotech funds to find which tickers are top holdings of multiple biotech hedge funds. Table 1 just shows companies in 5 to 6 funds. Upgrade to premium to see which are also held in more than 6...

Then see Table 2a for some of the Top 20s in the 36 Hedge Funds we have analyzed.

Table 1. A few top occurrences of companies in Top 20 of Hedge Funds*

Table 2a. Top 20 stock positions held by biotech hedge funds in Q2 2023**

**Tables 2a is color coded based on the prevalence of the ticker in the hedge funds Top 20s. Darker green colored cells have the highest occurrence and lighter green colored cells have less occurrences (with the lightest green showing 5 occurrences). Refer to Table 1 to see specific numbers of occurrences for each ticker.

See our premium article for the second half of the hedge funds and their Top 20s.

Table 3. Number of funds holding a biopharma company based on Market Cap.

This article is NOT legal, investment or tax advice. Please do your own diligence before making any investments.

Article history:

8/15/23 first posted RB


If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.

Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!


See what our members are saying about us:

Mike from United States

“Really loving the site over the competitor... like the layout and speed over the the individual pages for each drug/treatment”

Carl from United States

“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”

Essey from Canada

“Love what you’re doing, this website is awesome.”

James from United States

Great site and I see it’s a family run business, great job.”



bottom of page